Recent Posts
Deals•Feb 19, 2026
Altesa Raises $75M for Oral Respiratory Med
Altesa announced a $75 million fundraising round to develop its oral respiratory medication. The capital will support further clinical development and commercialization efforts.
Endpoints News
Deals•Feb 18, 2026
Faeth Goes Public via Merger with Sensei, Raising $200M
Faeth announced its public listing through a merger with Sensei, generating $200 million from a stock sale. The transaction marks Faeth's entry into the public markets.
Endpoints News
Deals•Feb 17, 2026
Six Biotech Companies File for HKEX IPOs
Six biotechnology firms have filed for initial public offerings on the Hong Kong Stock Exchange, signaling a push into Asian capital markets. The filings were announced on February 17, 2026.
Endpoints News
Deals•Feb 13, 2026
Gilead Acquires Global Rights to Genhouse Bio's Oral Cancer Drug for $80M
Gilead announced it will acquire the global rights to an oral cancer drug from China-based biotech Genhouse Bio, paying $80 million upfront. The deal expands Gilead's oncology pipeline as Genhouse prepares for a Hong Kong IPO.
Endpoints News
Deals•Feb 10, 2026
Cascade Pharmaceuticals Raises $72M to Develop MASH, Obesity and Diabetes Drugs
Shanghai-based biotech Cascade Pharmaceuticals announced it has secured $72 million (about 500 million yuan) in new funding to advance its pipeline targeting metabolic-associated steatohepatitis (MASH), obesity, and diabetes. The capital will support preclinical and clinical development of its drug candidates.
Endpoints News
Deals•Feb 10, 2026
ILiAD Biotechnologies Secures $115M Series B to Advance Whooping Cough Vaccine
ILiAD Biotechnologies announced an oversubscribed $115 million Series B financing on Tuesday. The new capital will fund pivotal Phase 3 trials for its whooping cough vaccine, accelerating development and potential market entry.
Endpoints News
Deals•Feb 9, 2026
QuantX Biosciences Secures $85M Series B Funding Led by Lilly and Sanofi Ventures
China‑American biotech QuantX Biosciences announced a $85 million Series B round, led by the venture arms of Eli Lilly and Sanofi. The funding will accelerate its immunology pipeline targeting key immune‑related diseases. The round highlights strong investor interest in biotech innovations.
Endpoints News
Deals•Feb 6, 2026
Agomab Therapeutics and SpyGlass Pharma Set to IPO on Friday
Fibrosis‑focused Agomab Therapeutics and eye‑disease company SpyGlass Pharma announced they will go public on Friday, marking a significant week for biotech IPOs. The offerings are expected to boost the biotech sector's comeback after a slowdown.
Endpoints News
News•Feb 5, 2026
White House Launches TrumpRx
The White House unveiled TrumpRx, a new direct‑to‑consumer website that lets Americans compare prescription drug prices and find lower‑cost options. The platform pulls real‑time pricing data from pharmacies, insurers and manufacturers, and provides discount coupons and pharmacy locators. TrumpRx is...
By Endpoints News
News•Feb 5, 2026
Veradermics CEO Has a Great Hair Day with 122% Pop in IPO
Veradermics, a biotech developing an oral formulation of minoxidil, saw its shares soar 122% on the first day of trading. The company aims to capture the growing consumer demand for hair‑loss solutions, positioning its product as a convenient alternative to...
By Endpoints News
News•Feb 5, 2026
#ISC26: Bayer’s Asundexian Reduced Ischemic Strokes by 26% in Phase 3 Trial
Bayer announced that its next‑generation factor XIa inhibitor asundexian cut ischemic stroke incidence by 26% in a pivotal Phase 3 trial for secondary stroke prevention. The study also reported a favorable safety profile, with fewer major bleeding events compared with standard anticoagulants....
By Endpoints News
News•Feb 5, 2026
Bristol Myers Draws Pipeline Excitement as Several Data Readouts Near
Bristol Myers Squibb highlighted at least ten late‑stage data readouts slated for 2024, reigniting investor enthusiasm after a period of muted pipeline news. The readouts span oncology, immunology and rare disease programs, many of which could support new label extensions...
By Endpoints News
News•Feb 5, 2026
GLP-1s and the Super Bowl
Hims & Hers launched a new Super Bowl commercial promoting GLP‑1 weight‑loss drugs, positioning the brand amid a surge in public interest. The ad directly calls out disparities in healthcare access, contrasting affluent consumers’ ability to afford the medication with...
By Endpoints News
News•Feb 5, 2026
Thermo Fisher, Charles River Workforce Cuts; WuXi Signs Contract with Vertex
Thermo Fisher Scientific announced the closure of its chemical analysis manufacturing site in Franklin, Massachusetts, citing current customer demand shifts. The shutdown will affect the plant’s workforce, adding to a wave of staffing reductions across the life‑science services sector, including...
By Endpoints News
News•Feb 5, 2026
Telehealth Provider Hims Goes After Novo's Weight Loss Pill with Compounded Version
Hims & Hers announced it will begin selling a compounded version of Novo Nordisk's Wegovy weight‑loss injection on Thursday, just weeks after the FDA approved the brand‑name drug. The telehealth firm positions the lower‑cost alternative as a more accessible option...
By Endpoints News
News•Feb 5, 2026
Eikon IPO Analysis: Big Biotech Names, Big Valuation Cut
Eikon Therapeutics, a Bay Area biotech that has raised more than $1 billion, launched its initial public offering this week. The IPO was priced at a valuation significantly lower than the $2 billion range previously projected, reflecting a broader pullback in biotech...
By Endpoints News
News•Feb 5, 2026
Eisai Gains Henlius Therapy; LB Pharma Snags $100M in Funding
Eisai announced an exclusive commercial license with China’s Henlius to sell the anti‑PD‑1 antibody serplulimab in Japan. The agreement gives Eisai sole rights to market the immunotherapy, positioning it alongside the company’s existing oncology portfolio. Serplulimab, a checkpoint inhibitor, is...
By Endpoints News
News•Feb 5, 2026
Angitia Gets $130M Series D for Pipeline of Musculoskeletal Drugs
Angitia Biopharmaceuticals announced a $130 million Series D financing round, led by a consortium of U.S. and Chinese investors. The capital will fund three biologic candidates currently in clinical trials for musculoskeletal disorders. One candidate targets a disease where Ultragenyx recently reported...
By Endpoints News
News•Feb 5, 2026
Flagship's Generate:Biomedicines Files for IPO, Pitching AI-Driven Drugs
Generate:Biomedicines, the Flagship Pioneering‑backed AI drug‑discovery startup, filed for an initial public offering just nine days after dosing its first patient in a Phase 3 trial. The company has positioned itself as a leading, heavily funded player in the emerging AI‑bio...
By Endpoints News
Deals•Feb 5, 2026
Generate:Biomedicines Files for IPO to Commercialize AI-Driven Drugs
Generate:Biomedicines, a Flagship Pioneering-backed AI bio startup, has filed for an initial public offering just nine days after dosing its first patient in a Phase 3 trial. The filing signals the company’s move to raise capital and bring AI-driven drug...
Endpoints News
Deals•Feb 5, 2026
Veradermics Surges 122% on Debut as Biotech Goes Public
Biotech firm Veradermics, developing an oral form of Rogaine, completed its initial public offering, with its shares jumping 122% on the first day of trading. The strong debut reflects investor enthusiasm for the growing aesthetics market and the company's innovative...
Endpoints News
Deals•Feb 5, 2026
Angitia Biopharma Secures $130M Series D to Advance Musculoskeletal Drug Pipeline
US-China biotech Angitia Biopharmaceuticals announced a $130 million Series D financing to support three biologics in clinical testing for musculoskeletal diseases. The funding will advance its pipeline, including a candidate that previously fell short at Ultragenyx, highlighting investor confidence in...
Endpoints News
Deals•Feb 5, 2026
Eikon Therapeutics Announces IPO Amid Valuation Cut
Bay Area biotech startup Eikon Therapeutics is preparing for an initial public offering, shifting from its $1 billion fundraising history. The analysis highlights a significant valuation cut as the company moves toward going public, marking a major event in the biotech...
Endpoints News
News•Feb 4, 2026
FTC Settles Insulin Lawsuit with Express Scripts
The Federal Trade Commission reached a settlement with pharmacy‑benefit manager Express Scripts over its handling of insulin rebates, securing an agreement that extends across virtually every segment of the company’s operations. The deal requires changes to rebate structures, increased transparency,...
By Endpoints News
News•Feb 4, 2026
AbbVie Says Immunology Blockbusters Will Be 'Main Drivers' Of Growth Post-Humira
AbbVie announced that its newer immunology drugs are compensating for the imminent loss of Humira’s patent protection. The combined sales of Skyrizi and Rinvoq have already surpassed Humira’s historic peak, signaling a successful transition to next‑generation biologics. The company frames...
By Endpoints News
News•Feb 4, 2026
Rare Pediatric PRV Program Reauthorized Until 2029 via Government Funding Law
President Donald Trump signed a government funding extension that also reauthorizes the FDA’s rare pediatric priority review voucher (PRV) program through 2029. The legislation revives the incentive mechanism that awards vouchers to sponsors of approved treatments for rare pediatric diseases,...
By Endpoints News
News•Feb 4, 2026
Midi Health Raises $100M as It Plans Expansion Into Urgent Care, Research
Midi Health, the pandemic‑born women’s health platform, announced a $100 million financing round that pushes its valuation past the $1 billion unicorn threshold. The capital, led by a consortium of venture firms, will fund the launch of a nationwide urgent‑care network and...
By Endpoints News
News•Feb 4, 2026
Hims Adds Grail's Cancer Test Amid Questions About Widespread Use
Hims & Hers, the telehealth consumer‑health brand, announced a partnership with Grail to offer the Galleri multi‑cancer early‑detection blood test on its platform. The move brings a technology that can screen for more than 50 cancer types to a broader,...
By Endpoints News
News•Feb 4, 2026
Novartis Says Generics to Erode $4B From 2026 Sales
Novartis announced that generic competition will erode about $4 billion from its 2026 sales, primarily affecting three blockbuster drugs. The heart‑failure medication Entrezto, its top seller, will see its first generic entry in the fourth quarter of 2026. The company warned...
By Endpoints News
News•Feb 4, 2026
Lilly Beats Sales Forecasts, Plots Major Growth in 2026 in Stark Contrast to Novo
Eli Lilly reported fourth‑quarter 2025 revenue that topped analysts’ forecasts, signaling a stronger‑than‑expected performance. The company also projected a sizable revenue increase for 2026, driven by upcoming product launches and an expanding oncology pipeline. This upbeat guidance contrasts sharply with Novo Nordisk’s...
By Endpoints News
News•Feb 4, 2026
Embattled Novo Nordisk Considers Buying a Monthly GLP-1 to Bolster Portfolio
Novo Nordisk is actively exploring the acquisition or internal development of a long‑acting, once‑monthly GLP‑1 therapy. The move aims to counter Pfizer’s newly launched monthly obesity injection and to broaden Novo’s weight‑loss portfolio. Executives see a monthly formulation as a...
By Endpoints News
News•Feb 4, 2026
FDA Seeks Withdrawal of Amgen's Tavneos, Company Says It Won't Pull Drug
The U.S. Food and Drug Administration has formally asked Amgen to withdraw its rare‑disease therapy Tavneos from the market, citing unresolved safety and manufacturing concerns. Amgen’s CEO Bob Bradway publicly rejected the request, stating the company will continue to sell...
By Endpoints News
News•Feb 3, 2026
Novo Expects Sales to Fall in 2026, Triggering Selloff
Novo Nordisk announced it expects sales to decline by at least 5% in 2026, marking the first projected contraction in years. The slowdown is driven by adverse pricing dynamics, notably the U.S. government’s new price caps on GLP‑1 therapies. The...
By Endpoints News
News•Feb 3, 2026
'Turning Around the Titanic': How the Incoming PBM Reforms Will Transform CMS
The Centers for Medicare & Medicaid Services (CMS) is set to roll out sweeping pharmacy‑benefit‑manager (PBM) reforms that will impose transparency, rebate‑disclosure, and reporting requirements on the industry. The rulemaking, slated for finalization in early 2025, targets the opaque pricing...
By Endpoints News
News•Feb 3, 2026
China Startup AccurEdit Raises $75M for Gene Editing Therapies
AccurEdit, a Chinese biotech startup, closed a $75 million Series B round to accelerate its CRISPR‑based gene‑editing therapies. The funding, led by Hillhouse Capital and Sequoia China, will finance IND‑enabling studies and scale GMP manufacturing. Early preclinical data show over 90 percent editing...
By Endpoints News
News•Feb 3, 2026
Daiichi Ends Work on an ADC; Layoffs at GSK's R&D Unit
Daiichi Sankyo announced it is terminating development of its antibody‑drug conjugate (ADC) program aimed at solid‑tumor indications, citing strategic reprioritisation and cost considerations. The cancellation eliminates an estimated $200 million of projected R&D spend. Meanwhile, GlaxoSmithKline disclosed a reduction of roughly...
By Endpoints News
News•Feb 3, 2026
Pfizer Takes $4.4B Charge Related to Cancer Drug in Fourth-Quarter Earnings
Pfizer reported fourth‑quarter earnings that included a $4.4 billion non‑cash charge tied to a recent high‑profile cancer‑drug acquisition. The write‑down lowered net income but the company highlighted a positive Phase III readout for a separate oncology candidate. Management said the data could...
By Endpoints News
News•Feb 3, 2026
Pfizer’s Metsera-Originated Monthly GLP-1 Cuts Weight by 10.5% at Six Months
Pfizer announced that its monthly GLP‑1 obesity drug, originated from the Metsera acquisition, achieved an average 10.5% weight reduction after six months in a late‑stage study. The therapy’s once‑monthly dosing is designed to improve patient adherence compared with weekly injectables....
By Endpoints News
News•Feb 3, 2026
AstraZeneca Gets CRL for Prefilled Pen Version of Lupus Drug Saphnelo
The U.S. Food and Drug Administration issued a Complete Response Letter (CRL) for AstraZeneca's subcutaneous prefilled‑pen version of Saphnelo, its anifrolumab therapy for systemic lupus erythematosus (SLE). The CRL indicates the agency found deficiencies—primarily around additional safety and manufacturing data—requiring...
By Endpoints News
Deals•Feb 3, 2026
Menlo Ventures and A16z Back AI Startup Phylo in Undisclosed Funding Round
Menlo Ventures and Andreessen Horowitz (a16z) have invested in Phylo, an AI scientist startup founded by Stanford researchers Le Cong, Yuanhao Qu, Kexin Huang, and Jure Leskovec. The funding round was announced on February 3, 2026, with undisclosed terms.
Endpoints News
News•Feb 2, 2026
Carbon Health Files for Bankruptcy, Seeking to Sell or Restructure
Carbon Health, a fast‑growing urgent and primary‑care startup, announced it has filed for Chapter 11 bankruptcy protection. The filing aims to either restructure the business or find a buyer. The company, which previously raised more than $800 million and operated hundreds...
By Endpoints News
News•Feb 2, 2026
First 10 Medicare-Negotiated Drug Prices Have Taken Effect: Are Seniors Really Saving Money?
The first ten drugs subject to Medicare price negotiations under the Inflation Reduction Act took effect in early 2024, with the government projecting billions of dollars in annual savings. Early data indicate that the negotiated caps have lowered list prices...
By Endpoints News
News•Feb 2, 2026
New CagriSema Data Show Improvement over Semaglutide
Novo Nordisk disclosed Phase III data showing its next‑generation metabolic therapy CagriSema outperformed the GLP‑1 blockbuster semaglutide in type 2 diabetes. The trial reported larger reductions in HbA1c and greater body‑weight loss while maintaining a comparable safety profile. CagriSema’s superiority was observed...
By Endpoints News
News•Feb 2, 2026
GSK Returns Rights to Wave's RNA Editing Program for AATD
GlaxoSmithKline has terminated its collaboration with Wave Life Sciences, returning all rights to the RNA‑editing program aimed at treating alpha‑1 antitrypsin deficiency (AATD). The decision ends a partnership that was closely watched as a potential first‑in‑class RNA‑editing therapy. GSK will...
By Endpoints News
News•Feb 2, 2026
FDA Rejects Aquestive's Allergy Drug over Packaging Issues
The U.S. Food and Drug Administration issued a complete response letter to Aquestive Therapeutics, rejecting its allergy medication because of packaging deficiencies. The agency identified labeling and child‑resistance failures that do not meet federal standards. As a result, the drug’s...
By Endpoints News
News•Feb 2, 2026
FDA Opens Submissions for PreCheck Program to Speed up US Factory Builds
The U.S. Food and Drug Administration has opened the first round of submissions for its new PreCheck program, designed to accelerate the construction and approval of drug manufacturing facilities. By allowing manufacturers to submit detailed construction plans early, the initiative...
By Endpoints News
News•Feb 2, 2026
Sanofi’s Venglustat Succeeds in Phase 3 Gaucher Trial but Fails Separate Study in Fabry Disease
Sanofi’s substrate‑reduction therapy venglustat met its primary endpoint in a Phase 3 trial for type 1 Gaucher disease, showing statistically significant reductions in glucosylceramide levels and improved organ volumes. The study enrolled 400 patients across North America and Europe and demonstrated a...
By Endpoints News
News•Feb 2, 2026
European Law Changes Mean Drugmakers May Have to Grapple with Generic Competition Sooner
European regulators are preparing a suite of new laws that will tighten the timeline for generic and biosimilar entry, shortening data‑exclusivity periods and expanding patent‑linkage requirements. The measures aim to force originator drugmakers to confront competition earlier, potentially shaving 15‑20%...
By Endpoints News
News•Jan 30, 2026
FDA Says It Explained Issues Early on for Corcept's Rejected Cushing's Syndrome Drug
The U.S. Food and Drug Administration issued a formal rejection of Corcept Therapeutics' experimental treatment for Cushing's syndrome, stating that it had raised serious scientific concerns early in the review process. FDA officials say they communicated these issues to Corcept...
By Endpoints News
News•Jan 30, 2026
Bitterroot Reverts to Preclinical Biotech in CD47 as CEO Leaves
Bitterroot Bio, a specialist in CD47 immunotherapy, announced that its program has reverted to the pre‑clinical discovery stage after a brief push toward clinical development. The move coincides with the unexpected resignation of its chief executive officer, raising questions about...
By Endpoints News
News•Jan 30, 2026
CHMP Opposes Lilly’s Mounjaro in Heart Failure, Backs Novo’s Kayshild
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) voted against extending Eli Lilly’s weight‑loss drug tirzepatide (Mounjaro) to treat heart failure, citing insufficient efficacy data. In the same meeting, the CHMP gave a positive opinion to...
By Endpoints News
News•Jan 30, 2026
Ultragenyx Resubmits Gene Therapy for Rare Neuro Disease to FDA
Ultragenyx has re‑submitted its FDA approval request for UX111, an adeno‑associated virus (AAV) gene‑therapy targeting a rare neurodegenerative disease. The company previously faced a complete response letter last summer, prompting additional pre‑clinical work and safety analyses. UX111 aims to replace...
By Endpoints News
News•Jan 30, 2026
Quince's Steroid Therapy for Rare Disease Fails, Shares Tank
Quince Therapeutics announced that its once‑monthly steroid‑based therapy for ataxia‑telangiectasia failed to meet the primary endpoint in a pivotal Phase 3 trial. The rare genetic disorder affects roughly 1 in 100,000 children and currently lacks disease‑modifying treatments. Following the data...
By Endpoints News
News•Jan 30, 2026
Moderna Licenses Phase 3 Asset to Recordati; ProMIS' Private Placement
Moderna has signed a licensing agreement with Italy’s Recordati to transfer a Phase 3 rare‑disease mRNA therapeutic to the European drugmaker. The deal provides Recordati with worldwide commercialization rights, an upfront cash payment estimated at $150 million, and a series of development...
By Endpoints News
News•Jan 30, 2026
Amgen Ends Partnership with Kyowa Kirin on Immunology Drug, Despite Phase 3 Wins
Amgen abruptly terminated its collaboration with Japan’s Kyowa Kirin on a late‑stage immunology candidate, returning all rights to the partner despite the drug’s recent Phase 3 success. The move aligns with Amgen’s broader strategic shift toward internal R&D priorities and upcoming biosimilar...
By Endpoints News
News•Jan 30, 2026
Lilly Unveils $3.5B Factory that Will Make Retatrutide and Other Obesity Drugs
Eli Lilly has allocated $3.5 billion to build a new manufacturing complex in Pennsylvania’s Lehigh Valley that will produce its next‑generation obesity injectable retatrutide and related compounds. The plant is designed for flexible, single‑use bioreactor technology and aims to output over a...
By Endpoints News
News•Jan 30, 2026
Janux Hires CMO After T Cell Engager Deal with Bristol Myers; A Batch of Appointments at Lexeo
Janux Therapeutics announced the appointment of William Go, M.D., Ph.D., as its new chief medical officer, replacing Zachariah McIver. The hire follows a recently disclosed partnership with Bristol Myers Squibb that provides a $50 million upfront payment for Janux’s T‑cell engager...
By Endpoints News
News•Jan 30, 2026
Reed Jobs' Cancer Biotech Investment Firm Yosemite Eyes $350M Fund
Yosemite, the cancer‑research investment firm led by Reed Jobs, is seeking to raise a fund of up to $350 million. The capital target positions the firm among the largest early‑stage biotech funds currently forming. Jobs leverages his Silicon Valley connections and...
By Endpoints News
News•Jan 29, 2026
Takeda 'Anticipated' Medicare Negotiations for Top Seller Entyvio
Takeda’s incoming CEO Julie Kim said the company anticipated Medicare’s selection of Entyvio for upcoming coverage negotiations. Entyvio, Takeda’s top-selling inflammatory‑bowel‑disease biologic, generated roughly $2.5 billion in 2023 revenue. While the firm expects a constructive dialogue, it has not disclosed pricing...
By Endpoints News
News•Jan 29, 2026
Takeda Is ‘Not in Favor’ of Trump’s MFN Deals, CEO-Designate Says
Takeda’s incoming chief executive publicly stated that the company is not supportive of President Donald Trump’s proposed “most favored nation” (MFN) agreements with pharmaceutical manufacturers. The MFN framework would grant U.S. drugmakers preferential pricing and market‑access terms, a move Takeda...
By Endpoints News
News•Jan 29, 2026
The Disrupted Fate of Pharmacy Startups
The House Judiciary Committee released a report alleging that CVS Health engaged in antitrust practices to suppress disruptive pharmacy startups. The findings highlight potential collusion with insurers and pharmacy benefit managers to limit market entry. Industry observers note that the...
By Endpoints News
Deals•Jan 29, 2026
Premise Health to Merge with Crossover Health to Expand Employer Clinics
Premise Health, an advanced primary care provider, announced a merger with Crossover Health, which runs on‑site health clinics for large employers such as Google and Amazon. The combined company aims to broaden its employer clinic network and help control rising...
Endpoints News
Deals•Jan 29, 2026
Agomab Therapeutics Targets $182M Nasdaq IPO to Fund Fibrosis Pipeline
Belgian biotech Agomab Therapeutics announced plans for a Nasdaq IPO to raise approximately $182 million in net proceeds. The capital will support the development of its fibrosis drug pipeline, with the company aiming to sell 12.5 million shares. The offering...
Endpoints News
Deals•Jan 28, 2026
Cellares Secures $257M Series D Funding to Accelerate Global Expansion and Target 2027 IPO
Clinical-stage cell therapy manufacturer Cellares announced a $257 million Series D funding round to support its global expansion and commercial rollout. The capital will also fund preparations for a planned initial public offering in 2027, highlighting investor confidence in its...
Endpoints News
Deals•Jan 28, 2026
Veradermics Targets $181.8M Net Proceeds in Upcoming IPO
Biotech firm Veradermics, developing an oral version of Rogaine, announced plans to go public and raise approximately $181.8 million in net proceeds. The proposed IPO will fund late‑stage testing and commercialization of its hair‑loss treatment.
Endpoints News
Deals•Jan 27, 2026
TRexBio Raises $50M in Series B Extension for Treg Clinical Development
Bay Area biotech TRexBio announced an additional $50 million to its 2024 Series B round, aimed at advancing its pipeline of regulatory T cell (Treg) candidates into clinical trials. The funding will support further development and expansion of its immunotherapy...
Endpoints News
Deals•Jan 27, 2026
Insilico Medicine Secures $120M Drug Discovery Pact with Qilu Pharma
Insilico Medicine announced a $120 million partnership with Chinese pharmaceutical firm Qilu Pharma to develop cardiometabolic therapies. The collaboration will leverage Insilico's AI-driven drug discovery platform to accelerate the identification of novel candidates. The deal highlights growing interest in AI-powered...
Endpoints News
Deals•Jan 27, 2026
Wisp Acquires Sexual Health Startup TBD Health
Virtual women's health platform Wisp announced the acquisition of sexual healthcare startup TBD Health, expanding its tele‑health services. The deal, reported on Jan. 27, 2026, aims to broaden Wisp's offerings in women's sexual health.
Endpoints News
Deals•Jan 27, 2026
Boehringer Ingelheim to Acquire IBD Bispecific From Simcere for €42M
German pharma Boehringer Ingelheim has agreed to pay €42 million upfront to Shanghai-based Simcere Pharmaceutical for an IBD bispecific drug candidate, marking a new partnership in immunology.
Endpoints News
Deals•Jan 22, 2026
BioMarin Veterans Launch New Biotech, Raise $82M for Rare Disease Drug Development
Former BioMarin executives have founded a new biotech focused on rare disease therapeutics. The startup announced an $82 million fundraising round to support development of orphan drugs. The capital will be used to acquire and advance promising rare disease candidates.
Endpoints News
Deals•Jan 22, 2026
Erasca Announces Upsized Public Offering of Common Stock
Erasca announced the pricing of an upsized public offering of its common stock, aiming to raise over $500 million. The offering, part of a broader $500M+ target for several biotech firms, was disclosed in a press release on Jan. 22,...
Endpoints News
Deals•Jan 21, 2026
Claim Health Secures $4.4M Funding to Streamline Home Care Payments
Claim Health, a health‑tech startup, announced a $4.4 million fundraising round to develop AI‑driven solutions that automate payment processes for home‑care providers. The capital will support product development and scaling, with investors not disclosed at the time of the announcement.
Endpoints News
Deals•Jan 20, 2026
Exciva Secures $59M Series B Funding to Advance Alzheimer’s Agitation Drug
Exciva announced a €51 million ($59 million) Series B financing round to fund Phase 2 testing of its candidate drug targeting agitation in Alzheimer’s disease. The capital will support clinical development and expand the company's pipeline.
Endpoints News
Deals•Jan 20, 2026
Shionogi Acquires Pfizer's Stake in ViiV, Doubling Its Ownership
Pfizer announced it will exit the HIV specialist joint venture ViiV, which it co‑founded with GSK. Shionogi will take over Pfizer’s share, doubling its stake in the company. The move reshapes ViiV’s ownership and strengthens Shionogi’s position in the HIV...
Endpoints News
Deals•Jan 20, 2026
GSK to Acquire RAPT for $2.2B
GlaxoSmithKline (GSK) announced a $2.2 billion acquisition of biotech firm RAPT, securing its food allergy candidate. The deal was unveiled at the JP Morgan Healthcare Conference, marking a major M&A move in the pharma sector.
Endpoints News
Deals•Jan 15, 2026
AbbVie Acquires Drug-Device Factory
Pharmaceutical giant AbbVie announced the acquisition of a drug-device manufacturing facility, expanding its presence in the medical device sector. The deal was reported on January 15, 2026, with financial terms undisclosed.
Endpoints News
Deals•Jan 12, 2026
Eli Lilly and Nvidia Sign Five‑year, up to $1 Billion AI Laboratory Deal
Eli Lilly and Nvidia have entered a five‑year partnership valued at up to $1 billion to create an AI laboratory aimed at accelerating drug discovery. The collaboration builds on a prior agreement to build pharma’s largest supercomputer and will leverage Nvidia’s...
Endpoints News
Deals•Jan 9, 2026
Aktis Oncology Lands Biotech's First IPO of 2026, Raising $318M
Aktis Oncology, a radiopharmaceutical startup partnered with Eli Lilly, announced its initial public offering on the Nasdaq, raising $318 million. The IPO marks the first biotech offering of 2026, positioning the company for growth in the radiopharma sector.
Endpoints News
Deals•Jan 9, 2026
Medipost Raises $140M to Expand Korean Stem Cell Therapy to US and Japan
South Korean biotech Medipost announced a $140 million fundraising round to commercialize its allogeneic cell therapy, approved in South Korea since 2012, in the United States and Japan. The capital will support regulatory approvals and market entry in these regions.
Endpoints News
Deals•Jan 8, 2026
Alveus Therapeutics Raises $159.8M in Series A to Expand Obesity Drug Pipeline
Alveus Therapeutics announced a $159.8 million Series A funding round on Thursday, aiming to accelerate its obesity drug development and challenge market leaders like tirzepatide and semaglutide. The capital will support the company's push into the space dominated by MariTide....
Endpoints News
Deals•Jan 8, 2026
Vizgen Raises $48M in Series E Round to Expand Spatial Biology and Multiomics Tools
Vizgen, a startup developing spatial biology and multiomics mapping technologies, announced a $48 million Series E funding round. The capital will be used to accelerate product development and market expansion. The round underscores continued investor interest in biotech innovation.
Endpoints News
Deals•Jan 8, 2026
Beacon Therapeutics Raises $75M Series C Led by Goldman Sachs Alternatives
Beacon Therapeutics announced a $75 million Series C financing round to advance its vision treatment pipeline. The round was led by Goldman Sachs Alternatives, with participation from a managing partner of the firm’s life sciences team. The funding aims to...
Endpoints News
Deals•Jan 8, 2026
French Biotech Enodia Therapeutics Raises €20.7M with Pfizer Backing
Enodia Therapeutics, a French biotech founded in February, announced it has raised €20.7 million (approximately $24 million) to develop protein degrader technology. The financing was aided by pharmaceutical giant Pfizer, marking a significant early-stage corporate investment in the company.
Endpoints News
Deals•Jan 8, 2026
Boltz Secures $28M Seed Funding to Build Open AI Models in Biology
Biotech startup Boltz announced a $28 million seed round to develop open AI models for biology. The funding will support the creation of large language models that predict biomolecular structures, building on advances like AlphaFold. The round highlights growing investor...
Endpoints News
Deals•Jan 8, 2026
Servier Launches €200M Corporate Venture Capital Unit for European Biotech Startups
French pharmaceutical group Servier announced the creation of a corporate venture capital unit focused on European biotech startups, initially funded with about €200 million ($232.9 million). The new VC arm aims to back emerging biotech innovations, joining a wave of large pharma...
Endpoints News
Deals•Jan 8, 2026
Parabilis Medicines Raises $305M to Tackle Undruggable Proteins
Parabilis Medicines announced a $305 million financing round to develop therapies targeting undruggable proteins. The capital will fuel its platform to address challenging protein targets, highlighting strong investor interest in biotech solutions for hard‑to‑drug diseases.
Endpoints News